A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
A Phase 1, Randomized, Participant- and Investigator-Blinded, Placebo Controlled, Single-Dose and Multiple-Ascending Dose Study of Orally Administered LY5625573 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein
The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also look at how the body absorbs, breaks down, and clears the study drug (pharmacokinetics), how the study drug works in the body, and whether it interacts with certain other medications by affecting how the body processes them.
Participation in the study will last up to approximately 7 weeks for Part A and 8.5 weeks for Parts B, C, D, and E. For each participant there will be one stay at the clinical research unit (CRU) lasting 5 nights for Part A, 18 nights for Parts B and C, and 17 nights for Parts D and E.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 전화번호: 1-317-615-4559
- 이메일: LillyTrials@Lilly.com
연구 연락처 백업
- 이름: Physicians interested in becoming principal investigators please contact
- 이메일: clinical_inquiry_hub@lilly.com
연구 장소
-
-
California
-
Los Alamitos, California, 미국, 90720
- 아직 모집하지 않음
- Collaborative Neuroscience Network - CNS
-
수석 연구원:
- Steven Reynolds
-
-
Texas
-
Dallas, Texas, 미국, 75247
- 모병
- Fortrea Clinical Research Unit
-
수석 연구원:
- Gene Voskuhl
-
연락하다:
- 전화번호: 866-429-3700
-
-
-
-
-
Singapore, 싱가포르, 138623
- 아직 모집하지 않음
- Lilly Centre for Clinical Pharmacology
-
연락하다:
- 전화번호: 64139811
-
수석 연구원:
- Jeffer Hann Wei Pang
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 21 to 65 years of age, inclusive, at the time of signing the informed consent if enrolled in Singapore
- Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring
- Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Have a hemoglobin level of at least 12.5 grams per deciliter (g/dL) for participants assigned male at birth (AMAB) and at least 11.4 g/dL for participants assigned female at birth (AFAB)
- Individuals AFAB who are individual not of childbearing potential (INOCBPs) may participate in this trial
Parts A, B, D, and E
- Have a body mass index (BMI) greater than or equal to (≥)18.5 and less than or equal to (≤) 32.0 kilograms per square meter (kg/m²)
- Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of ≥90 milliliter per minute per 1.73 square meters (mL)/minute/1.73 m² at screening
Part C
- Have a BMI ≥18.5 and <40.0 kg/m²
- high-sensitivity C-reactive protein (hsCRP) ≥2 milligrams per liter (mg/L) and ≤15 mg/L at screening and Day -2 (as confirmed by local laboratory).
- Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m² at screening
Part D
- To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan
Part E
- To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
Exclusion Criteria:
- History of active tuberculosis or presence of active or latent tuberculosis
- History or evidence of clinically significant opportunistic infection
- History of serious local infection (for example, cellulitis or abscess) or systemic infection within 90 days prior to screening
- Have any nonserious but active infections
- History of more than one episode of herpes zoster infection or history of disseminated herpes zoster infection
- Have a 12-lead electrocardiogram (ECG) abnormality
- Clinically significant abnormal laboratory test results at screening, or positive serology test results for hepatitis B surface antigen, hepatitis B core total antibody, hepatitis C virus antibody, or human immunodeficiency virus antigen and antibody, or QuantiFERON®-TB test at screening
Parts A, C, D, and E
- History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232) or to any excipient in the formulation of LY5625573
Part B
- History of significant allergic reactions to any medication or known allergic reactions to drugs related to LY5625573 (VTX3232), midazolam, or to any excipient in the formulation of LY5625573 or midazolam
Parts B, C, D, and E
- Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 90 days (at screening and/or Day -1 [Day 2 for Part B])
- Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire (at Day -1[Day 2 for Part B]
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: LY5625573 Part A - Single Dose Healthy
Single dose of LY5625573 administered orally in healthy participants |
Administered orally as tablet
다른 이름들:
|
|
위약 비교기: Placebo Part A - Single Dose Healthy
Single dose of Placebo administered orally in healthy participants |
Administered orally as tablet |
|
실험적: LY5625573 + Midazolam Part B - Multiple Dose Healthy
Multiple-ascending dose (MAD) of LY5625573 and midazolam co-administered orally in healthy participants |
Administered orally Administered orally as tablet
다른 이름들:
|
|
위약 비교기: Placebo + Midazolam Part B - Multiple Dose Healthy
Multiple doses of Placebo and midazolam co-administered orally in healthy participants |
Administered orally Administered orally as tablet |
|
실험적: LY5625573 Part C - Multiple Dose Elevated hsCRP
MAD of LY5625573 administered orally in participants with elevated high-sensitivity C-reactive protein (hsCRP) |
Administered orally as tablet
다른 이름들:
|
|
위약 비교기: Placebo Part C - Multiple Dose Elevated hsCRP
Multiple doses of Placebo administered orally in participants with elevated hsCRP |
Administered orally as tablet |
|
실험적: LY5625573 Part D - Healthy Japanese
MAD of LY5625573 administered orally in healthy Japanese participants |
Administered orally as tablet
다른 이름들:
|
|
위약 비교기: Placebo Part D - Healthy Japanese
Multiple doses of Placebo administered orally in healthy Japanese participants |
Administered orally as tablet |
|
실험적: LY5625573 Part E - Healthy Chinese
MAD of LY5625573 administered orally in healthy Chinese participants |
Administered orally as tablet
다른 이름들:
|
|
위약 비교기: Placebo Part E - Healthy Chinese
Multiple doses of Placebo administered orally in healthy Chinese participants |
Administered orally as tablet |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
기간: Baseline up to Follow up (Days 12 and 24)
|
Baseline up to Follow up (Days 12 and 24)
|
|
Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) Considered by the Investigator to be Related to Study Drug Administration
기간: Baseline up to Follow up (Days 12 and 24)
|
Baseline up to Follow up (Days 12 and 24)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY5625573
기간: Baseline up to End of Treatment (Day 17)
|
Baseline up to End of Treatment (Day 17)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 27937
- J7V-MC-EOBB (기타 식별자: Eli Lilly and Company)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .